Arvinas, Inc. (ARVN)
ARVN moved a median of -0.26% 30 minutes after news, and -0.12% by the close. How ARVN actually reacts to news — the realized, point-in-time move the market made, measured across 442 labeled events over the last three years with zero look-ahead.
ARVN’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.04% | 51% | 439 |
| 30-min | -0.26% | 42% | 441 |
| 60-min | -0.16% | 45% | 441 |
| to close | -0.12% | 49% | 442 |
| Middle 50% of ARVN reactions | -1.47% to +0.78% |
|---|---|
| Median reaction (30-min) | -0.26% |
| Measured reactions | 442 |
Half of all Arvinas, Inc. news events land between -1.47% and +0.78% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How ARVN reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 24 | -1.82% | 29% | -1.37% |
| Analyst downgrades | 33 | -0.57% | 42% | +3.07% |
| Coverage initiations | 10 | +1.04% | 60% | +1.13% |
| Rating reiterations | 120 | -0.07% | 46% | -0.17% |
| Price-target raises | 10 | +0.57% | 70% | +0.88% |
| Price-target cuts | 35 | -0.14% | 43% | +0.35% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. See how ARVN ranks against every other measured name →
That’s how ARVN usually reacts — get an email when it moves on news →Email me when ARVN moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ARVN's baseline. Nothing else.
Recent ARVN events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s Disease | Press release | GlobeNewswire | +0.14% | +2.76% | |
| Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders® | Press release | GlobeNewswire | -1.33% | -1.33% | |
| Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.80% | +2.45% | |
| Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate | Press release | GlobeNewswire | -0.73% | -0.40% | |
| Form S-8 ARVINAS, INC. | SEC filing · Form S-8 | SEC EDGAR | -0.40% | +0.13% | |
| Arvinas to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | -0.54% | +0.86% | |
| Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +3.13% | +3.34% | |
| Form S-8 ARVINAS, INC. | SEC filing · Form S-8 | SEC EDGAR | +0.88% | +1.53% | |
| Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +8.58% | +6.51% | |
| Form 10-Q ARVINAS, INC. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.23% | -4.76% | |
| Form 8-K ARVINAS, INC. For: Aug 04 | SEC filing · Form 8-K | SEC EDGAR | +8.58% | +6.51% | |
| Arvinas to Report Second Quarter 2026 Financial Results on August 4, 2026 | Press release | GlobeNewswire | -0.61% | -0.48% | |
| Form 8-K ARVINAS, INC. For: Jun 24 | SEC filing · Form 8-K | SEC EDGAR | -0.37% | -1.60% | |
| Form 8-K ARVINAS, INC. For: Jun 22 | SEC filing · Form 8-K | SEC EDGAR | +2.69% | +6.68% | |
| Form 8-K ARVINAS, INC. For: Jun 11 | SEC filing · Form 8-K | SEC EDGAR | +0.67% | +2.95% | |
| Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease | Press release | GlobeNewswire | +0.32% | -1.15% | |
| Form 8-K ARVINAS, INC. For: Jun 02 | SEC filing · Form 8-K | SEC EDGAR | -0.38% | -2.28% | |
| Arvinas to Present at Jefferies Global Healthcare Conference | Press release | GlobeNewswire | -1.22% | -4.77% | |
| Arvinas Employees Give Back During Company-wide Impact Day | Press release | GlobeNewswire | +0.00% | -1.35% | |
| Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant) | Press release | GlobeNewswire | -5.33% | -2.65% | |
| Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -5.33% | -2.65% | |
| Form 8-K ARVINAS, INC. For: May 11 | SEC filing · Form 8-K | SEC EDGAR | -5.33% | -2.65% | |
| Form 8-K ARVINAS, INC. For: May 12 | SEC filing · Form 8-K | SEC EDGAR | -5.33% | -2.65% | |
| Form 10-Q ARVINAS, INC. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -5.33% | -2.65% | |
| Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026 | Press release | GlobeNewswire | +0.37% | -1.76% | |
| Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer | Press release | GlobeNewswire | — | +2.34% | |
| Form 8-K ARVINAS, INC. For: May 01 | SEC filing · Form 8-K | SEC EDGAR | — | +2.34% | |
| Form ARS ARVINAS, INC. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.70% | -2.00% | |
| Form DEF 14A ARVINAS, INC. For: Jun 24 | SEC filing · Form DEF | SEC EDGAR | +0.66% | -1.01% | |
| Form DEFA14A ARVINAS, INC. | SEC filing · Form DEFA14A | SEC EDGAR | +0.66% | -1.01% | |
| Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days | Press release | GlobeNewswire | -1.82% | -7.95% | |
| Form 8-K ARVINAS, INC. For: Mar 18 | SEC filing · Form 8-K | SEC EDGAR | -1.82% | -7.95% | |
| Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders | Press release | GlobeNewswire | -0.29% | -1.89% | |
| Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -1.32% | +9.18% | |
| Form 10-K ARVINAS, INC. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +1.00% | +2.43% | |
| Form 8-K ARVINAS, INC. For: Feb 24 | SEC filing · Form 8-K | SEC EDGAR | -1.32% | +9.18% | |
| Form S-8 ARVINAS, INC. | SEC filing · Form S-8 | SEC EDGAR | +1.00% | +2.43% | |
| Arvinas to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +3.13% | +3.97% | |
| Arvinas to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 | Press release | GlobeNewswire | +0.61% | -1.04% | |
| Arvinas Announces Appointment of Randy Teel, Ph.D., as President, Chief Executive Officer, and Director | Press release | GlobeNewswire | -4.56% | -6.96% | |
| Form 8-K ARVINAS, INC. For: Feb 10 | SEC filing · Form 8-K | SEC EDGAR | -4.56% | -6.96% | |
| PROTAC Market Shows Accelerated Growth During the Forecast Period (2025-2034) Amid Rising Targeted Therapy Demand | DelveInsight | Press release | PR Newswire | -1.20% | -2.24% | |
| Form 8-K ARVINAS, INC. For: Dec 06 | SEC filing · Form 8-K | SEC EDGAR | +1.46% | +2.46% | |
| Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition | Press release | GlobeNewswire | +1.46% | +2.46% | |
| Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference | Press release | GlobeNewswire | +1.25% | +3.41% | |
| Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS) | Press release | GlobeNewswire | +0.52% | +1.47% | |
| Arvinas Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +1.43% | +1.49% | |
| Form 10-Q ARVINAS, INC. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.93% | +2.99% | |
| Form 8-K ARVINAS, INC. For: Nov 05 | SEC filing · Form 8-K | SEC EDGAR | +1.43% | +1.49% | |
| Arvinas to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | -1.58% | -4.14% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ARVN section they belong to.
Where else ARVN is measured.
ARVN earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| ROCHE HOLDING LTD S/ADR (RHHBY) | 449 | +0.03% | 52% |
| CareDx, Inc. (CDNA) | 443 | -0.11% | 47% |
| Jaguar Health, Inc. (JAGX) | 442 | -0.38% | 41% |
| BOVIE MEDICAL (BVX) | 441 | 0.00% | 46% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Arvinas, Inc.'s median reaction calculated?
Every labeled ARVN news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 442 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 42% of ARVN's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ARVN's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.